Gemini Smith

Создал новую статью

3 лет назад - перевести

Drug Development Targets in Ribosome | #ribosome

Drug Development Targets in Ribosome

Drug Development Targets in Ribosome

Similarly, previous reports confirmed that the addition of excessive EF Tu can restore the in vitro translation process of ribosomes in the presence of the EF Tu inhibitors such as amythiamycin.

Мне нравится

Комментарий

Перепост

Создал новую статью

3 лет назад - перевести

Asialoglycoprotein Receptor | #asialoglycoprotein Receptor

Asialoglycoprotein Receptor

Asialoglycoprotein Receptor

Cell surface carbohydrate lectins are known to orchestrate a variety of cellular and intercellular functions through specific recognition and binding to various receptors. Of these, the first mammalian cell membrane-bound lectin receptor discovered was ASGPR.

Мне нравится

Комментарий

Перепост

Создал новую статью

3 лет назад - перевести

The Midbody | #mammalian cells #midbody

The Midbody

The Midbody

We provide a comprehensive range of recombinant antibodies used in the research of the midbody.

Мне нравится

Комментарий

Перепост

Создал новую статью

3 лет назад - перевести

Bispecific Antibody Application in Radioimmunotherapy | #bispecific Antibody

Bispecific Antibody Application in Radioimmunotherapy

Bispecific Antibody Application in Radioimmunotherapy

With experienced experts hammering, we are confident in offering first class BsAbs to meet your project development needs.

Мне нравится

Комментарий

Перепост

изменила свою фотографию

3 лет назад

Мне нравится

Комментарий

Перепост

Загрузка заметок

Информация

5 сообщений
https://non-igg-ab.creative-biolabs.com
Женский
08-18-99
Страна Америка

О нас

With state-of-the-art equipment, functional facilities, and qualified scientists on staff, Creative Biolabs can offer tailored, one-stop solutions for the development of non-IgG antibodies. We offer customizable solutions to suit your needs, and every integrated project or stand-alone service we offer is expertly planned to satisfy each unique requirement.

0

0

Нравится

0

0